New drug cocktail shows promise for tough liver cancer
NCT ID NCT02519348
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This study tested different combinations of immune-boosting drugs (durvalumab, tremelimumab, and bevacizumab) in 433 adults with advanced liver cancer that had worsened after standard treatment. The goal was to see if these drugs are safe and can shrink tumors or slow the disease. While not a cure, the approach aims to give patients more time and better control over their cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Phoenix, Arizona, 85054, United States
-
Research Site
San Francisco, California, 94158, United States
-
Research Site
New Haven, Connecticut, 06510, United States
-
Research Site
Jacksonville, Florida, 32224, United States
-
Research Site
Tampa, Florida, 33612, United States
-
Research Site
Indianapolis, Indiana, 46202, United States
-
Research Site
Boston, Massachusetts, 02114, United States
-
Research Site
New York, New York, 10065, United States
-
Research Site
Stony Brook, New York, 11794, United States
-
Research Site
Durham, North Carolina, 27705, United States
-
Research Site
Portland, Oregon, 97213, United States
-
Research Site
Philadelphia, Pennsylvania, 19107, United States
-
Research Site
Philadelphia, Pennsylvania, 19111, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Dallas, Texas, 75390, United States
-
Research Site
Seattle, Washington, 98109, United States
-
Research Site
Hangzhou, 310016, China
-
Research Site
Nanjing, 210002, China
-
Research Site
Shanghai, 200032, China
-
Research Site
Hong Kong, Hong Kong
-
Research Site
Shatin, Hong Kong
-
Research Site
Benevento, 82100, Italy
-
Research Site
Milan, 20133, Italy
-
Research Site
Roma, 00168, Italy
-
Research Site
Chūōku, 104-0045, Japan
-
Research Site
Kashiwa, 277-8577, Japan
-
Research Site
Osakasayama-shi, 589-8511, Japan
-
Research Site
Bukit Merah, 169610, Singapore
-
Research Site
Singapore, 119074, Singapore
-
Research Site
Singapore, 308433, Singapore
-
Research Site
Busan, 49241, South Korea
-
Research Site
Junggu, 41944, South Korea
-
Research Site
Seongnam-si, 13620, South Korea
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 06273, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Barcelona, 08035, Spain
-
Research Site
Barcelona, 08036, Spain
-
Research Site
Córdoba, 14004, Spain
-
Research Site
Pamplona, 31008, Spain
-
Research Site
Kaohsiung City, 83301, Taiwan
-
Research Site
Taipei, 100, Taiwan
-
Research Site
Taoyuan City, 333, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?